Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors

被引:27
作者
Bulatova, Nailya [1 ]
Yousef, Al-Motassem [1 ]
Al-Khayyat, Ghada [1 ]
Qosa, Hisham [1 ]
机构
[1] Univ Jordan, Fac Pharm, Dept Biopharmaceut & Clin Pharm, Amman 11942, Jordan
关键词
Tacrolimus; adverse effects; living donors; kidney transplant; immunosuppression;
D O I
10.2174/157488611794480043
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The main objectives of this study were to estimate the prevalence of and the risk factors for the adverse effects of tacrolimus-based immunosuppression in patients who obtained renal transplant from living donors. Methods: A multicenter cross-sectional observational study in 154 kidney transplant patients who received grafts from living donors. Results: Large proportion of patients had hypertension (83%) and hyperlipidemia (53%); 27% had posttransplant diabetes mellitus. Patients had on average two chronic diseases. Tremor was present in 40%, neurologic toxicity in 45%, and anemia in 51.5% of patients. The average number of adverse effects was 3.52 +/- 1.57. In multivariate analysis some adverse effects were related to tacrolimus concentration, duration of treatment, number of medications or medical problems. In linear regression analysis correlation was found, among the others, between diastolic blood pressure and tacrolimus concentration, and inverse correlation between erythrocyte count and duration of treatment. Conclusion: There is a significant prevalence of tacrolimus adverse effects and supratherapeutic TAC blood concentrations in Jordanian renal transplant patients in spite of using low TAC doses and overall adequate renal function.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 44 条
[1]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[2]   Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs [J].
Araki, M ;
Flechner, SM ;
Ismail, HR ;
Flechner, LM ;
Zhou, LM ;
Derweesh, IH ;
Goldfarb, D ;
Modlin, C ;
Novick, AC ;
Faiman, C .
TRANSPLANTATION, 2006, 81 (03) :335-341
[3]  
Arms PA, 1988, PHARM APPROACH CRITI, P85
[4]  
Belbeisi A., 2006, Morbidity and Mortality Weekly Report, V55, P653
[5]   Mveloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: Characteristics, risk factors and prognosis [J].
Caillard, S ;
Agodoa, LY ;
Bohen, EM ;
Abbott, KC .
TRANSPLANTATION, 2006, 81 (06) :888-895
[6]   Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients [J].
Cheung, Chi Yuen ;
Wong, Kim Ming ;
Chan, Hoi Wong ;
Liu, Yan Lun ;
Chan, Yiu Han ;
Wong, Ho Sing ;
Chak, Wai Leung ;
Choi, Koon Shing ;
Chau, Ka Foon ;
Li, Chun Sang .
TRANSPLANT INTERNATIONAL, 2006, 19 (08) :657-666
[7]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]   A Randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis [J].
Ciancio, G ;
Burke, GW ;
Gaynor, JJ ;
Ruiz, P ;
Roth, D ;
Kupin, W ;
Rosen, A ;
Miller, J .
TRANSPLANTATION, 2006, 81 (06) :845-852
[9]  
Daly TM, 1996, NEW ENGL J MED, V334, P1749
[10]  
Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855